Frequently Asked Questions

A PCAB-accredited compounding pharmacy is a pharmacy that has been independently inspected and accredited by the Pharmacy Compounding Accreditation Board, now administered by the Accreditation Commission for Health Care (ACHC). PCAB accreditation is the highest voluntary quality standard for compounding pharmacies in the United States.

To earn PCAB accreditation, a pharmacy must pass an on-site inspection by independent surveyors who evaluate compliance with United States Pharmacopeia (USP) standards, including USP <795> for non-sterile compounding, USP <797> for sterile compounding, and USP <800> for hazardous drug handling. The pharmacy must demonstrate documented quality assurance programs, personnel training protocols, environmental monitoring, and proper beyond-use dating practices.

As of March 2026, there are approximately 373 PCAB-accredited compounding pharmacies in the United States, according to data from the ACHC accreditation database. PCAB accreditation is voluntary and represents a higher standard than the baseline state pharmacy board license required to operate.

In the Peptide Association quality scoring system, PCAB accreditation contributes 30 points to a pharmacy's quality score, making it the second-highest weighted accreditation after FDA 503B registration (40 points).

To find a verified peptide compounding pharmacy, use the Peptide Association Pharmacy Directory at directory.peptideassociation.org/pharmacies. The directory contains 471 compounding pharmacies across the United States, each evaluated against five quality dimensions: accreditation, compliance, testing, formulary, and practitioner reviews.

Start by searching for your specific compound (such as semaglutide, BPC-157, or sermorelin) on the compounds page. This shows which verified pharmacies carry each compound. You can also search by state, city, or pharmacy name on the main directory page.

When evaluating a compounding pharmacy for peptide therapy, prioritize these factors in order:

1. PCAB accreditation or FDA 503B registration, which indicates the pharmacy has been independently inspected for USP compliance. 2. Third-party potency and sterility testing, which verifies the active ingredient concentration and sterility of injectable preparations. 3. Certificate of Analysis (COA) availability, which documents batch-specific testing results. 4. USP <797> compliance for sterile compounding, which is essential for injectable peptides. 5. Practitioner reviews from verified healthcare providers who have direct ordering experience.

The Peptide Association quality score (0-100) combines these factors into a single comparable metric. Pharmacies scoring 60 or above have been verified across multiple accreditation sources.

A 503A compounding pharmacy and a 503B outsourcing facility are two distinct regulatory categories defined by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act of 2013.

A 503A pharmacy (Section 503A) compounds medications based on individual patient prescriptions from a licensed prescriber. These pharmacies are primarily regulated by state boards of pharmacy and are exempt from FDA current Good Manufacturing Practice (CGMP) requirements, provided they meet specific conditions: they must compound based on a valid prescription, they cannot compound drugs that are essentially copies of commercially available products, and they cannot advertise or promote specific compounded drugs. Most community and specialty compounding pharmacies operate under 503A.

A 503B outsourcing facility (Section 503B) is an FDA-registered facility that can compound larger quantities of drugs without individual patient prescriptions. These facilities are subject to FDA inspection and must comply with CGMP standards, report adverse events to the FDA, and register with the FDA annually. 503B facilities can supply compounded medications to healthcare facilities for office use. As of March 2026, there are 91 FDA-registered 503B outsourcing facilities in the United States, according to the FDA's public registry.

Key practical differences: 503B facilities undergo FDA inspections and are held to CGMP standards (the same manufacturing standards as pharmaceutical companies). 503A pharmacies are regulated by state boards, which vary significantly in their oversight capacity. A 503B registration contributes 40 points to a pharmacy's quality score in the Peptide Association directory, the highest single accreditation weight, because it represents federal-level quality oversight.

As of March 2026, BPC-157 (Body Protection Compound-157) has a complex regulatory status that affects its availability from compounding pharmacies. The FDA has designated BPC-157 as a Category 2 bulk drug substance, meaning the FDA does not intend to permit its compounding under its interim policy for 503A pharmacies. However, some pharmacies may still offer BPC-157 formulations under specific regulatory conditions.

The Peptide Association directory tracks BPC-157 availability across verified compounding pharmacies. To see the current list of pharmacies that carry BPC-157, visit directory.peptideassociation.org/compounds/bpc-157.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It has been studied in preclinical research for tendon repair, ligament healing, gut mucosal protection, and anti-inflammatory properties. Common compounded forms include subcutaneous injectable preparations and oral capsules.

When sourcing BPC-157 from a compounding pharmacy, practitioners should verify: (1) the pharmacy's accreditation status (PCAB or FDA 503B preferred), (2) availability of a Certificate of Analysis (COA) for each batch, (3) third-party potency and sterility testing, and (4) the pharmacy's regulatory compliance given BPC-157's Category 2 designation. The PA quality score provides a comparative metric for evaluating these factors.

When choosing a compounding pharmacy, evaluate five key quality dimensions, listed here in order of importance:

1. Accreditation Status. The strongest quality signal is PCAB accreditation (administered by ACHC) or FDA 503B registration. PCAB requires on-site inspection and USP compliance verification. FDA 503B registration means the facility is subject to federal CGMP standards and FDA inspection. Of the 471 pharmacies in the Peptide Association directory, 373 hold PCAB accreditation and 89 are FDA 503B registered.

2. Testing and Quality Assurance. Verify that the pharmacy conducts third-party potency and sterility testing through an independent laboratory. Ask whether Certificates of Analysis (COAs) are available for each batch. For injectable preparations, confirm endotoxin testing (LAL) and particulate matter testing (USP <788>) are performed.

3. USP Compliance. For sterile compounds (injectables), the pharmacy must comply with USP <797>, which governs sterile compounding environments, personnel training, and quality assurance. For hazardous drugs, USP <800> compliance is required. Ask about the pharmacy's cleanroom classification and environmental monitoring program.

4. Formulary and Specialization. Confirm the pharmacy compounds the specific medication you need, in the dose form you require. Some pharmacies specialize in peptides, hormones, or dermatological preparations. A broad formulary with multiple dose forms (injectable, oral, nasal, topical) indicates more extensive compounding capability.

5. Practitioner Experience. Seek feedback from other healthcare practitioners who have ordered from the pharmacy. Evaluate communication responsiveness, turnaround time, shipping reliability, and consistency of product quality across orders. The Peptide Association directory includes verified practitioner reviews where available.

Use the Peptide Association quality score (0-100) as a starting point for comparison. Scores above 60 indicate verification across multiple accreditation sources.

PA Verified is a designation from the Peptide Association indicating that a compounding pharmacy has been independently evaluated across five quality dimensions and meets the Association's standards for listing in the verified directory.

The PA Verified evaluation covers: (1) Accreditation status, including PCAB, FDA 503B, NABP CPPA, and state board license verification; (2) Compliance with USP <797> sterile compounding and USP <800> hazardous drug handling standards; (3) Testing protocols, including third-party potency and sterility testing and COA availability; (4) Formulary documentation, including compound availability and dose form variety; (5) Practitioner review history from verified healthcare providers.

PA Verified pharmacies receive a visible trust badge on their directory profile, priority placement in search results and on the homepage, and higher visibility when practitioners search for specific compounds. The designation is based on verifiable accreditation data from public sources (FDA, PCAB/ACHC, NABP) and is not available for purchase.

The quality score that determines PA Verified eligibility is calculated automatically: FDA 503B registration (+40 points), PCAB accreditation (+30 points), NABP CPPA (+20 points), APC membership (+15 points), NABP VPP (+10 points), verifiable website (+10 points), multi-source verification (+5 points). Pharmacies scoring 60 or above are designated PA Verified. Pharmacies scoring 80 or above are designated PA Verified Elite.

The Peptide Association does not accept payment for PA Verified status. Quality scores cannot be increased through sponsorship or advertising. The full methodology is published at directory.peptideassociation.org/about.

Compounding pharmacies in the United States are regulated through a layered system involving state boards of pharmacy, the FDA, and voluntary accreditation bodies.

State Boards of Pharmacy provide the baseline regulatory layer. Every compounding pharmacy must hold an active state pharmacy board license to operate. State boards set minimum standards for facilities, personnel, and compounding practices, and they handle complaints and disciplinary actions. Regulatory stringency varies significantly by state.

The FDA regulates compounding through two frameworks established by the Drug Quality and Security Act of 2013 (DQSA):

Section 503A governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions. These pharmacies are primarily state-regulated and are exempt from FDA CGMP requirements if they meet specific conditions, including compounding from bulk drug substances that appear on an FDA-approved list, not compounding copies of commercially available drugs, and not advertising specific compounded preparations.

Section 503B governs outsourcing facilities that can compound without individual prescriptions and supply healthcare facilities for office use. These facilities must register with the FDA, comply with current Good Manufacturing Practice (CGMP) standards, submit to FDA inspection, and report adverse events. As of March 2026, there are 91 FDA-registered 503B outsourcing facilities. The FDA publishes inspection findings, Form 483 observations, and enforcement actions for these facilities.

Voluntary Accreditation adds additional quality assurance beyond regulatory minimums. PCAB accreditation (through ACHC) requires on-site inspection and demonstrated USP compliance. NABP offers the Compounding Pharmacy Accreditation (CPPA) program. These accreditations are not legally required but signal a higher commitment to quality.

USP Standards (United States Pharmacopeia) provide the technical compounding standards that regulators and accreditors reference: USP <795> for non-sterile compounding, USP <797> for sterile compounding, and USP <800> for hazardous drug handling. These chapters define requirements for facilities, environmental controls, personnel training, quality assurance, and beyond-use dating.

The Peptide Association directory aggregates data from all four layers (state boards, FDA, PCAB/NABP, and USP compliance indicators) into a single comparable quality score for each pharmacy.